Welcome to our dedicated page for Milestone Scientific news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scientific stock.
Milestone Scientific, Inc. (NASDAQ: MLSS) is a pioneering company in the field of medical and dental anesthesia. The company focuses on the development, manufacture, marketing, and sale of computer-controlled local anesthetic delivery (C-CLAD) systems designed to provide improved and painless local anesthetic delivery. These systems are marketed under various trademarks for different applications. For dentistry, the products are known as CompuDent™ and STA™ (Single Tooth Anesthesia) System. These innovative devices allow for painless injections during a wide range of dental procedures, from routine cleanings to complex surgeries involving implants, root canals, and crowns.
For medical applications, Milestone Scientific offers similar technology under the CompuMed™ trademark. Their products are used across various medical disciplines, including plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, and orthopedics. The company's advanced anesthetic delivery systems are sold both in the United States and in over 25 countries worldwide, highlighting their global reach and impact.
Besides their core product offerings, Milestone Scientific also provides The Wand™, a handpiece that allows for almost painless injections, enhancing patient comfort significantly.
The firm's operations are divided into two main segments: Dental and Medical. Geographically, all operations are concentrated in the United States, but their products are influential on a global scale.
Recent Achievements:
- Successful evaluations by prominent medical professionals, such as Dr. Matthew Stottle of Omaha Pain Physicians, achieving 100% success rates.
- Acceleration in reimbursement claims submission for the CompuFlo® Epidural System.
For more information or inquiries, Milestone Scientific can be contacted through Crescendo Communications, LLC via email at mlss@crescendo-ir.com or by phone at 212-671-1020.
Milestone Scientific (NYSE American: MLSS) announced that Interim CEO Leonard Osser has completed a share sale to cover option costs and taxes, resulting in an increase in his common stock holdings. Osser has submitted Form 4s detailing these transactions and stated he has no plans for further sales. Milestone Scientific specializes in developing computerized drug delivery instruments using its proprietary technology for various medical applications. The company emphasizes its focus on innovation in painless injection technology.
Milestone Scientific (NYSE American: MLSS) has raised its revenue guidance for Q4 2020 to over $2 million, marking a 67% increase from $1.2 million in Q3 2020. This optimistic outlook is attributed to a recovery in the dental sector as dental offices reopen. Notably, this figure excludes recent sales of approximately $450,000 to a Chinese distributor. The company is also gaining traction with its CompuFlo® Epidural System, having started sales of disposables to the University of Texas Medical Branch, with plans to expand to more hospitals.
Milestone Scientific (NYSE American: MLSS) released a survey revealing insights from Board Certified Anesthesiologists regarding the future of anesthesiology. Conducted by the Schlesinger Group, the survey found that 56% of anesthesiologists feel time pressures affect patient care, and 84% believe their skills are underutilized. Notably, 96% emphasize the need for new technologies. Milestone aims to lead this change with products like the CompuFlo Epidural System, which could reduce procedure complications and costs. A webinar detailing these findings is scheduled for January 12, 2021.
Milestone Scientific Inc. (MLSS) has initiated sales of its CompuFlo disposables to the University of Texas Medical Branch (UTMB), following a purchase order received in late 2020. The CompuFlo system is designed to enhance safety and efficiency in epidural procedures, reducing complication rates and anesthesia time. It is projected to deliver significant economic benefits, with a study indicating an average savings of $504 per hospital stay compared to traditional methods. Both hospital and physician responses have been positive, suggesting a favorable outlook for future commercial opportunities.
Milestone Scientific (NYSE American:MLSS) announced that Interim CEO Leonard Osser intends to exercise up to 336,970 options. He plans to sell some shares to fund the options and cover taxes, but this will increase his total common stock holdings. Osser confirmed he will not sell additional shares. The company specializes in innovative, computerized drug delivery systems designed to provide painless injections for medical, dental, and cosmetic applications.
Milestone Scientific (MLSS) anticipates a significant sales increase for Q4 2020, forecasting at least $1.7 million, marking a 40% sequential growth from Q3. The uptick is attributed to recovering dental operations post-pandemic and improved cash flow. The company has terminated exclusive distribution rights with Henry Schein, enhancing market penetration opportunities. The Wand® STA instrument's safety and efficiency are emphasized as it supports dental practices during COVID-19. Recent sales to a Chinese distributor of approximately $450,000 are expected but won’t be recorded until resold.
Milestone Scientific (MLSS) reported significant third-quarter developments. Dental sales rose over seven-fold compared to Q2 2020, aided by marketing promotions after COVID-19 disruptions. The company secured a purchasing agreement with Premier, enhancing its hospital reach. Despite this growth, Q3 revenues fell to approximately $1.2 million from $1.9 million year-over-year, with gross profit dropping to 67%. Operating loss increased to $(1.5) million due to reduced dental revenue. Cash reserves stood at over $14 million, supporting ongoing marketing and operational efforts.
Milestone Scientific Inc. (MLSS) will present at the Virtual Fall Investor Summit from November 16-18, 2020. Interim CEO Leonard Osser is scheduled to speak on November 18 at 9:30 a.m. ET. The presentation will be streamed live and available for replay. Investors can register for the conference or schedule one-on-one meetings through the Investor Summit Group. Milestone Scientific is known for its innovative injection technologies, focusing on precision and painlessness in medical and dental applications.
Milestone Scientific Inc. (NYSE: MLSS) announced a conference call for 8:30 AM ET on November 17, 2020, to discuss its third-quarter financial results for the period ending September 30, 2020. The call will address the company's corporate progress and developments. Interested parties can access the call via the company's website or by dialing specific numbers for U.S. and international callers. Milestone Scientific is known for its innovative computerized drug delivery instruments aimed at providing painless injections.
Milestone Scientific (MLSS) has published a video interview featuring Dr. Ayman A. Alian from Yale School of Medicine. The interview showcases the CompuFlo® Epidural System and CathCheck™, highlighting their benefits in improving epidural procedures. Dr. Alian emphasizes that these technologies enhance block efficiency, reduce complications, and improve patient satisfaction. CEO Arjan Haverhals expresses gratitude for Dr. Alian's support, reinforcing the technology's potential to become the standard in care.
FAQ
What is the current stock price of Milestone Scientific (MLSS)?
What is the market cap of Milestone Scientific (MLSS)?
What does Milestone Scientific, Inc. do?
What are the main products offered by Milestone Scientific?
Where are Milestone Scientific’s products sold?
What recent achievements has Milestone Scientific accomplished?
What are the main segments of Milestone Scientific’s business?
How can Milestone Scientific be contacted?
What is The Wand™?
What is the STA™ System?
Which medical disciplines use Milestone Scientific’s systems?
What is CompuMed™?
